Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-18-120614
Filing Date
2018-04-18
Accepted
2018-04-18 12:06:33
Documents
10
Effectiveness Date
2018-04-18

Document Format Files

Seq Description Document Type Size
1 DEFA14A d520996ddefa14a.htm DEFA14A 30964
2 GRAPHIC g520996g22a02.jpg GRAPHIC 4961
3 GRAPHIC g520996g34u25.jpg GRAPHIC 9569
4 GRAPHIC g520996g35k40.jpg GRAPHIC 9014
5 GRAPHIC g520996g42r48.jpg GRAPHIC 3549
6 GRAPHIC g520996g54c49.jpg GRAPHIC 18532
7 GRAPHIC g520996g69k96.jpg GRAPHIC 8392
8 GRAPHIC g520996g79c18.jpg GRAPHIC 5093
9 GRAPHIC g520996g86k34.jpg GRAPHIC 5022
10 GRAPHIC g520996g91b43.jpg GRAPHIC 82363
  Complete submission text file 0001193125-18-120614.txt   235095
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-22873 | Film No.: 18760621
SIC: 2835 In Vitro & In Vivo Diagnostic Substances